NovaSight

NovaSight develops eye-tracking-based vision care solutions for children, combining eye tracking technology and data analytics to revolutionize pediatric vision care. The company's two flagship products are CureSight, an FDA-cleared and CE-marked at-home amblyopia treatment system designed to replace traditional eye patching, and TrackSight, a software-based solution for myopia prevention and vision health monitoring. CureSight provides remote digital amblyopia treatment through a patented approach that uses eye tracking to monitor and modify content displayed to each eye individually, enabling dichoptic treatment without the social stigma and discomfort of physical patches. TrackSight offers myopia management and prevention through software-based vision health monitoring. NovaSight's technology utilizes optical IR sensors that track and record momentary gaze position 90 times per second, proprietary ActiveSight glasses providing remote-controlled eye occlusion with distance and tilt measurements, and AI-powered big data analytics that correlate eye patterns to create vision population norms for clinical assessment and treatment decisions. The platform is designed specifically for children, with screening, assessment, and treatment delivered through fun, entertaining, and child-friendly activities that maximize comfort and engagement. The objective measurement approach does not rely on patient cooperation or operator skills, raising the eye-care standard with greater accuracy and repeatability than legacy solutions while reducing chair time and accelerating treatment. Founded in 2016 and headquartered in Lod, Israel, with a US office in Lewes, Delaware, NovaSight has raised $20.0M in Series B funding from investors including Rimonci and EIT Health.